Monoclonal anti-acid-labile subunit oligopeptide antibodies and their use in a two-site immunoassay for ALS measurement in humans

Simone Stadler, Zida Wu, Regina A. Dressendörfer, Katherine M. Morrison, Aruna Khare, Phillip Lee, Christian J. Strasburger

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Quantification of the acid-labile subunit (ALS) has to date been restricted to immunoassays utilizing polyclonal antibodies. By immunization with N-terminal and C-terminal specific ALS oligopeptides, we generated monoclonal antibodies (mAbs) that target ALS-specific sequences outside the nonspecific leucine-rich repeats in the ALS molecule. For mAb selection, a special screening method was developed. Monoclonal antibody 5C9, which targets the N-terminus of ALS, is immobilized and the anti-ALS mAb 7H3, directed against the C-terminus, is biotinylated and used as tracer Ab. Due to the extreme pH-lability of ALS, changes in immunorecognition of ALS were investigated after acidification for protein unfolding in different pH ranges and in a time-dependent manner. It was determined that acidification of the serum samples to pH 2.7 for 30 min, followed by neutralization and dilution to 1:100 was the optimal acid-neutralization method. For standardization purposes, a serum pool derived from healthy volunteers was assigned the value 1 U/ml ALS. The sandwich assay has a working range with a linear dose-response curve in a log/log system between 0.005 and 10 U/ml. ALS levels in seven acromegalic patients ranged from 2.0 to 4.2 U/ml, and in 12 untreated growth hormone deficient patients from 0.036 to 0.986 U/ml (mean = 0.45 U/ml). After 12 months of growth hormone therapy, ALS levels increased significantly to 1.18 ± 0.45 U/ml (mean ± SD; p< 0.0006). The increase ranged from 0.48 to 1.4 U/ml. The change in ALS with growth hormone (GH) therapy correlated closer with the change in IGF-I (r = 0.798, p = 0.0057; Spearman rank correlation) than with the change in insulin-like growth factor binding protein (IGFBP3; r = 0.549, p = 0.057). This specific sandwich assay for the measurement of ALS provides a potentially valuable indicator of growth hormone secretory status. With this mAb-based immunofluorometric assay, the nonspecific detection of other proteins containing leucine-rich repeat sequences can be excluded.

Original languageEnglish (US)
Pages (from-to)73-82
Number of pages10
JournalJournal of Immunological Methods
Volume252
Issue number1-2
DOIs
StatePublished - Jun 1 2001
Externally publishedYes

Fingerprint

Oligopeptides
Immunoassay
Acids
Antibodies
Growth Hormone
Monoclonal Antibodies
Fluoroimmunoassay
Protein Unfolding
Insulin-Like Growth Factor Binding Proteins
Serum
Insulin-Like Growth Factor I
Leucine

Keywords

  • ALS
  • Fluorescence assay
  • IGF-I
  • IGFBP3
  • Monoclonal antibodies

ASJC Scopus subject areas

  • Biotechnology
  • Immunology

Cite this

Monoclonal anti-acid-labile subunit oligopeptide antibodies and their use in a two-site immunoassay for ALS measurement in humans. / Stadler, Simone; Wu, Zida; Dressendörfer, Regina A.; Morrison, Katherine M.; Khare, Aruna; Lee, Phillip; Strasburger, Christian J.

In: Journal of Immunological Methods, Vol. 252, No. 1-2, 01.06.2001, p. 73-82.

Research output: Contribution to journalArticle

Stadler, Simone ; Wu, Zida ; Dressendörfer, Regina A. ; Morrison, Katherine M. ; Khare, Aruna ; Lee, Phillip ; Strasburger, Christian J. / Monoclonal anti-acid-labile subunit oligopeptide antibodies and their use in a two-site immunoassay for ALS measurement in humans. In: Journal of Immunological Methods. 2001 ; Vol. 252, No. 1-2. pp. 73-82.
@article{e5af27607d384ab7a60142a2a13433f6,
title = "Monoclonal anti-acid-labile subunit oligopeptide antibodies and their use in a two-site immunoassay for ALS measurement in humans",
abstract = "Quantification of the acid-labile subunit (ALS) has to date been restricted to immunoassays utilizing polyclonal antibodies. By immunization with N-terminal and C-terminal specific ALS oligopeptides, we generated monoclonal antibodies (mAbs) that target ALS-specific sequences outside the nonspecific leucine-rich repeats in the ALS molecule. For mAb selection, a special screening method was developed. Monoclonal antibody 5C9, which targets the N-terminus of ALS, is immobilized and the anti-ALS mAb 7H3, directed against the C-terminus, is biotinylated and used as tracer Ab. Due to the extreme pH-lability of ALS, changes in immunorecognition of ALS were investigated after acidification for protein unfolding in different pH ranges and in a time-dependent manner. It was determined that acidification of the serum samples to pH 2.7 for 30 min, followed by neutralization and dilution to 1:100 was the optimal acid-neutralization method. For standardization purposes, a serum pool derived from healthy volunteers was assigned the value 1 U/ml ALS. The sandwich assay has a working range with a linear dose-response curve in a log/log system between 0.005 and 10 U/ml. ALS levels in seven acromegalic patients ranged from 2.0 to 4.2 U/ml, and in 12 untreated growth hormone deficient patients from 0.036 to 0.986 U/ml (mean = 0.45 U/ml). After 12 months of growth hormone therapy, ALS levels increased significantly to 1.18 ± 0.45 U/ml (mean ± SD; p< 0.0006). The increase ranged from 0.48 to 1.4 U/ml. The change in ALS with growth hormone (GH) therapy correlated closer with the change in IGF-I (r = 0.798, p = 0.0057; Spearman rank correlation) than with the change in insulin-like growth factor binding protein (IGFBP3; r = 0.549, p = 0.057). This specific sandwich assay for the measurement of ALS provides a potentially valuable indicator of growth hormone secretory status. With this mAb-based immunofluorometric assay, the nonspecific detection of other proteins containing leucine-rich repeat sequences can be excluded.",
keywords = "ALS, Fluorescence assay, IGF-I, IGFBP3, Monoclonal antibodies",
author = "Simone Stadler and Zida Wu and Dressend{\"o}rfer, {Regina A.} and Morrison, {Katherine M.} and Aruna Khare and Phillip Lee and Strasburger, {Christian J.}",
year = "2001",
month = "6",
day = "1",
doi = "10.1016/S0022-1759(01)00335-0",
language = "English (US)",
volume = "252",
pages = "73--82",
journal = "Journal of Immunological Methods",
issn = "0022-1759",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Monoclonal anti-acid-labile subunit oligopeptide antibodies and their use in a two-site immunoassay for ALS measurement in humans

AU - Stadler, Simone

AU - Wu, Zida

AU - Dressendörfer, Regina A.

AU - Morrison, Katherine M.

AU - Khare, Aruna

AU - Lee, Phillip

AU - Strasburger, Christian J.

PY - 2001/6/1

Y1 - 2001/6/1

N2 - Quantification of the acid-labile subunit (ALS) has to date been restricted to immunoassays utilizing polyclonal antibodies. By immunization with N-terminal and C-terminal specific ALS oligopeptides, we generated monoclonal antibodies (mAbs) that target ALS-specific sequences outside the nonspecific leucine-rich repeats in the ALS molecule. For mAb selection, a special screening method was developed. Monoclonal antibody 5C9, which targets the N-terminus of ALS, is immobilized and the anti-ALS mAb 7H3, directed against the C-terminus, is biotinylated and used as tracer Ab. Due to the extreme pH-lability of ALS, changes in immunorecognition of ALS were investigated after acidification for protein unfolding in different pH ranges and in a time-dependent manner. It was determined that acidification of the serum samples to pH 2.7 for 30 min, followed by neutralization and dilution to 1:100 was the optimal acid-neutralization method. For standardization purposes, a serum pool derived from healthy volunteers was assigned the value 1 U/ml ALS. The sandwich assay has a working range with a linear dose-response curve in a log/log system between 0.005 and 10 U/ml. ALS levels in seven acromegalic patients ranged from 2.0 to 4.2 U/ml, and in 12 untreated growth hormone deficient patients from 0.036 to 0.986 U/ml (mean = 0.45 U/ml). After 12 months of growth hormone therapy, ALS levels increased significantly to 1.18 ± 0.45 U/ml (mean ± SD; p< 0.0006). The increase ranged from 0.48 to 1.4 U/ml. The change in ALS with growth hormone (GH) therapy correlated closer with the change in IGF-I (r = 0.798, p = 0.0057; Spearman rank correlation) than with the change in insulin-like growth factor binding protein (IGFBP3; r = 0.549, p = 0.057). This specific sandwich assay for the measurement of ALS provides a potentially valuable indicator of growth hormone secretory status. With this mAb-based immunofluorometric assay, the nonspecific detection of other proteins containing leucine-rich repeat sequences can be excluded.

AB - Quantification of the acid-labile subunit (ALS) has to date been restricted to immunoassays utilizing polyclonal antibodies. By immunization with N-terminal and C-terminal specific ALS oligopeptides, we generated monoclonal antibodies (mAbs) that target ALS-specific sequences outside the nonspecific leucine-rich repeats in the ALS molecule. For mAb selection, a special screening method was developed. Monoclonal antibody 5C9, which targets the N-terminus of ALS, is immobilized and the anti-ALS mAb 7H3, directed against the C-terminus, is biotinylated and used as tracer Ab. Due to the extreme pH-lability of ALS, changes in immunorecognition of ALS were investigated after acidification for protein unfolding in different pH ranges and in a time-dependent manner. It was determined that acidification of the serum samples to pH 2.7 for 30 min, followed by neutralization and dilution to 1:100 was the optimal acid-neutralization method. For standardization purposes, a serum pool derived from healthy volunteers was assigned the value 1 U/ml ALS. The sandwich assay has a working range with a linear dose-response curve in a log/log system between 0.005 and 10 U/ml. ALS levels in seven acromegalic patients ranged from 2.0 to 4.2 U/ml, and in 12 untreated growth hormone deficient patients from 0.036 to 0.986 U/ml (mean = 0.45 U/ml). After 12 months of growth hormone therapy, ALS levels increased significantly to 1.18 ± 0.45 U/ml (mean ± SD; p< 0.0006). The increase ranged from 0.48 to 1.4 U/ml. The change in ALS with growth hormone (GH) therapy correlated closer with the change in IGF-I (r = 0.798, p = 0.0057; Spearman rank correlation) than with the change in insulin-like growth factor binding protein (IGFBP3; r = 0.549, p = 0.057). This specific sandwich assay for the measurement of ALS provides a potentially valuable indicator of growth hormone secretory status. With this mAb-based immunofluorometric assay, the nonspecific detection of other proteins containing leucine-rich repeat sequences can be excluded.

KW - ALS

KW - Fluorescence assay

KW - IGF-I

KW - IGFBP3

KW - Monoclonal antibodies

UR - http://www.scopus.com/inward/record.url?scp=0035371852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035371852&partnerID=8YFLogxK

U2 - 10.1016/S0022-1759(01)00335-0

DO - 10.1016/S0022-1759(01)00335-0

M3 - Article

VL - 252

SP - 73

EP - 82

JO - Journal of Immunological Methods

JF - Journal of Immunological Methods

SN - 0022-1759

IS - 1-2

ER -